Did Stryker's reported EPS growth reflect underlying operating performance?

Only partly. Reported diluted EPS rose 33.1% to $2.05, but this included a $41 million tax benefit (about $0.11 per share) from discrete tax items. Adjusted diluted EPS, which excludes these and other special items such as amortization and restructuring, grew a more modest 16.8% to $2.50. Investors typically focus on the adjusted figure for trend analysis.

What drove the change in Stryker's full-year 2024 guidance?

Management raised organic net sales growth guidance to 8.5%-9.5%, citing the strong first quarter, healthy procedure volumes, and demand for capital products. Adjusted EPS guidance was set at $11.85-$12.05. Management expects FX to moderately reduce reported sales and to weigh on EPS toward the high end of its previously guided $0.05-$0.10 impact, though it reiterated its commitment to expanding operating margins.

Why was operating cash flow weak in the quarter?

Net cash from operations was $204 million versus $445 million in Q1 2023. The decline was driven by an $844 million outflow from changes in operating assets, liabilities, and taxes, which more than offset $788 million of net earnings plus non-cash items. Inventories rose to $5.0 billion from $4.8 billion, though accounts receivable declined, suggesting that timing of working capital may reverse over the year.

Which business segment performed best, and what is driving it?

MedSurg and Neurotechnology grew 11.5% reported (11.6% organic), with 10.2% from unit volume and 1.4% from pricing. Instruments (+17.7% in the U.S.) and Medical (+11.0% in the U.S.) were strong contributors. Orthopaedics and Spine grew 7.5%, led by Trauma and Extremities (+7.9%) and Other (+41.2%), while Knees and Hips grew more slowly at 4.0% and 5.1%.

Is Stryker's balance sheet or debt position a concern?

Cash fell to $2.3 billion from $3.0 billion, largely due to the working capital build, dividend payments of $304 million, and a $246 million acquisition. Long-term debt was roughly stable at $10.8 billion, and shareholders' equity rose to $19.2 billion. The company remains leveraged but is still generating positive earnings and maintaining its dividend, so leverage is a monitoring item rather than an immediate concern.

SYK 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed April 30, 2024. Cited figures are marked; the original filing is the authoritative source.

Stryker (SYK) reported a strong first quarter 2024 on April 30, 2024, with reported net sales up 9.7% to $5.2 billion^a and organic net sales up 10.0%, driven by 9.3% unit volume growth and 0.7% price.

MedSurg and Neurotechnology was the standout, growing 11.5% reported (11.6% organic), while Orthopaedics and Spine grew 7.5% reported (8.0% organic). Profitability improved meaningfully: reported operating margin rose to 18.5% from 15.4%, adjusted operating margin expanded 80 bps to 21.9%, and reported diluted EPS climbed 33.1% to $2.05^b. Adjusted diluted EPS grew 16.8% to $2.50, though the reported EPS gain was flattered by a $41 million net tax benefit from discrete tax matters, so investors should focus on the adjusted figures for underlying trends.

Management raised its full-year 2024 organic sales growth outlook to 8.5%-9.5% (pricing roughly flat) and set adjusted diluted EPS guidance at $11.85^c-$12.05, up from the prior range. Management noted that foreign exchange is expected to moderately reduce reported net sales, weighing more heavily in the first half, and to pressure adjusted EPS toward the higher end of the previously guided $0.05-$0.10 headwind. Operating cash flow was weak at $204 million versus $445 million a year earlier, driven by a $844 million outflow from working capital changes, with inventories and receivables movements being the key drivers of the shortfall.

Overall, the quarter shows broad-based demand, solid volume-led growth, and margin expansion, supporting a constructive view on the raised guidance. The main watch items are the cash conversion shortfall, FX headwinds, and the reliance on non-GAAP measures to show underlying earnings growth.

02—Key points

Key Highlights

Reported net sales rose 9.7% to $5.2 billion (organic +10.0%), with unit volume contributing 9.3% of organic growth.
MedSurg and Neurotechnology led growth at 11.5% reported (11.6% organic), while Orthopaedics and Spine grew 7.5% reported (8.0% organic).
Adjusted operating margin expanded 80 bps to 21.9%; reported operating margin improved to 18.5% from 15.4%.
Adjusted diluted EPS grew 16.8% to $2.50; reported diluted EPS rose 33.1% to $2.05, aided by a $41 million net tax benefit.
Full-year 2024 organic sales growth guidance raised to 8.5%-9.5%; adjusted diluted EPS guidance set at $11.85-$12.05.
Operating cash flow fell to $204 million from $445 million, pressured by an $844 million working capital outflow; inventories rose to $5.0 billion.
Foreign exchange is expected to moderately reduce full-year reported net sales, with the impact more pronounced in the first half of 2024.

03—Questions

Frequently Asked Questions

Did Stryker's reported EPS growth reflect underlying operating performance?
Only partly. Reported diluted EPS rose 33.1% to $2.05, but this included a $41 million tax benefit (about $0.11 per share) from discrete tax items. Adjusted diluted EPS, which excludes these and other special items such as amortization and restructuring, grew a more modest 16.8% to $2.50. Investors typically focus on the adjusted figure for trend analysis.
What drove the change in Stryker's full-year 2024 guidance?
Management raised organic net sales growth guidance to 8.5%-9.5%, citing the strong first quarter, healthy procedure volumes, and demand for capital products. Adjusted EPS guidance was set at $11.85-$12.05. Management expects FX to moderately reduce reported sales and to weigh on EPS toward the high end of its previously guided $0.05-$0.10 impact, though it reiterated its commitment to expanding operating margins.
Why was operating cash flow weak in the quarter?
Net cash from operations was $204 million versus $445 million in Q1 2023. The decline was driven by an $844 million outflow from changes in operating assets, liabilities, and taxes, which more than offset $788 million of net earnings plus non-cash items. Inventories rose to $5.0 billion from $4.8 billion, though accounts receivable declined, suggesting that timing of working capital may reverse over the year.
Which business segment performed best, and what is driving it?
MedSurg and Neurotechnology grew 11.5% reported (11.6% organic), with 10.2% from unit volume and 1.4% from pricing. Instruments (+17.7% in the U.S.) and Medical (+11.0% in the U.S.) were strong contributors. Orthopaedics and Spine grew 7.5%, led by Trauma and Extremities (+7.9%) and Other (+41.2%), while Knees and Hips grew more slowly at 4.0% and 5.1%.
Is Stryker's balance sheet or debt position a concern?
Cash fell to $2.3 billion from $3.0 billion, largely due to the working capital build, dividend payments of $304 million, and a $246 million acquisition. Long-term debt was roughly stable at $10.8 billion, and shareholders' equity rose to $19.2 billion. The company remains leveraged but is still generating positive earnings and maintaining its dividend, so leverage is a monitoring item rather than an immediate concern.

04—Continue

← View all 8-K filings